GGrantIndex
← Leaderboards

Penelope Jane Hallett

Mclean Hospital

$5,641,169
Attributed
$15,584,892
Total exposure
4
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.4M · FY201524
$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$15,584,892 · 4

By mechanism

U01$9,168,144 · 1
R01$4,132,452 · 2
RF1$2,284,296 · 1

Most similar at Mclean Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Brain

Research focus

BrainSynapsesExperimental StudyInduced Pluripotent Stem CellParkinson DiseaseCellsAlzheimer&AposMidbrain StructureNeuronsDopaminergic NeuronParkinsonian DisordersNeurodegenerative DisordersNerve DegenerationIn VitroFunctional DisorderPathologyS DiseaseDisease ModelDesignMutationAlpha SynucleinIn Vitro TestingIn VivoGlycosphingolipids

Grant awards (17)

Parkinsons Disease Scalable iPSC Autologous Cell Therapy$1,958,850
U01 · FY2024 · NS · contact PI
ApoE, lipid and immune mechanisms of human neurons and glia$2,284,296
RF1 · FY2023 · AG
Parkinsons Disease Scalable iPSC Autologous Cell Therapy$1,961,294
U01 · FY2023 · NS · contact PI
Parkinsons disease scalable iPSC autologous cell therapy$164,000
U01 · FY2023 · NS · contact PI
Parkinsons Disease Scalable iPSC Autologous Cell Therapy$1,640,000
U01 · FY2022 · NS · contact PI
Prevention of complement and immune-mediated Lewy body dementia$563,846
R01 · FY2022 · AG
Parkinsons disease scalable iPSC autologous cell therapy$164,000
U01 · FY2022 · NS · contact PI
Parkinsons disease scalable iPSC autologous cell therapy$1,640,000
U01 · FY2021 · NS · contact PI
Prevention of complement and immune-mediated Lewy body dementia$569,300
R01 · FY2021 · AG
Parkinsons disease scalable iPSC autologous cell therapy$1,640,000
U01 · FY2020 · NS · contact PI
Prevention of complement and immune-mediated Lewy body dementia$574,594
R01 · FY2020 · AG
Prevention of complement and immune-mediated Lewy body dementia$579,735
R01 · FY2019 · AG
Prevention of complement and immune-mediated Lewy body dementia$600,725
R01 · FY2018 · AG
Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease$311,063
R01 · FY2018 · NS · contact PI
Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease$311,063
R01 · FY2017 · NS · contact PI
Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease$311,063
R01 · FY2016 · NS · contact PI
Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease$311,063
R01 · FY2015 · NS · contact PI